| 764458 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
620 Onco-immunological mechanisms of focal ablation and localized IL-12 immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.620 |
Vrabel Maura, Zaharoff David, Mantooth Siena |
| 764457 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
618 Expanding cancer immunotherapy by exploiting recall immunity – A new co-therapy option for checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.618 |
Brown Kathlynn, McGuire Michael, Pande Anuja, Venugopal Indu |
| 764456 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.422 |
Miest Tanner, Leibovich Bradley, Bardot Stephen, Young Paul, Boorjian Stephen, Gonzalgo Mark, Herrera-Hernandez Loren, Tollefson Matthew, Karnes Jeffrey, Nichols Paige, Kroeninger Tessa, Graham Rachel, Lahana Carole, Reckner Monica, Newsom Alysha, Packiriswamy Nandakumar, Anoka Janice, Peng Kah Whye, Wiegert Erol, Bexon Alice, Naik Shruthi |
| 764455 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.420 |
Bailey Shania, Lassoued Wiem, Papanicolau-Sengos Antonios, Marte Jennifer, Williams Nikki, Hankin Amy, Manu Michell, Dahut William, Pinto Peter, Karzai Fatima, Madan Ravi, Sater Houssein Abdul, Gulley James |
| 764454 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.418 |
Bono Johann De, Shore Neal, Kramer Gero, Joshua Anthony, Li Xin Tong, Poehlein Christian, Schloss Charles, Yu Evan |
| 764453 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.417 |
Choueiri Toni, Plimack Elizabeth, Powles Thomas, Voss Martin, Gurney Howard, Silverman Rachel, Perini Rodolfo, Rodriguez-Lopez Karla, Rini Brian |
| 764452 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
416 An open-label phase 2 study of 2 doses of the hypoxia-inducible factor (HIF)–2α inhibitor belzutifan for the treatment of advanced clear cell renal cell carcinoma after progression on systemic therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.416 |
Atkins Michael, Liu Yanfang, Perini Rodolfo, Roy Ananya, Haanen John |
| 764451 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
414 A randomized phase II study of systemic therapy plus WeiLeShu (WLS) versus systemic therapy alone in patients with metastatic colorectal cancer (mCRC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.414 |
Zhang Ruyi, Tu Xiaoxuan, Tong Zhou, Zhang Hangyu, Zhu Xudong, Fang Weijia, Yu Lanfang, Mou Haibo |
| 764450 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
413 Toripalimab in combination with concurrent chemoradiation in patients with advanced/metastatic esophageal carcinoma: protocol for a single-arm, prospective, open-label, phase II clinical trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.413 |
Wu Lei, Wang Yi, Wan Gang, Lv Jiahua, Wang Qifeng, Lang Jinyi, Li Tao |
| 764449 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
412 CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.412 |
Tong Zhou, Lu Sen, Dai Xiaomeng, Cheng Xiaobin, Bao Xuanwen, Zhu Xudong, Cheng Xiaofei, Fu Qihan, Wang Danyang, Zhang Hangyu, Sheng Qinsong, Liu Lulu, Zhang Guoliang, Zheng Yi, Liu Fanlong, Zhao Peng, Chen Wenbin, Fang Weijia, Xu Xiangmin |
